Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Takeda
>
Did Yasu say...No more layoffs?
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 4332720"]Well first off your rules are wrong. Last I checked revenue is all money coming in not just a certain selected group of income earners. Obviously the field sales products will not be generating the huge sales revenue like the past. Leadership has acknowledge this and stated the plan is to bottom the next several years and regain growth as new products enter the market and others grow...something like 2017ish return to past revenue. So with that as the plan you DO INCLUDE all products knowing that they are bridging us to the future.</p><p><br /></p><p>These are from 3rd qtr and do not include any grow factor.</p><p><br /></p><p>Dexilant: $296 Million yr</p><p>Uloric: $160 Million yr</p><p>Edarbi/Family $4 Million yr (much higher then these #'s)</p><p>Amitiza: $232 Million yr</p><p>Colcyrs: $430 Million yr</p><p>Prevacid: $232 Million yr</p><p>Prevacid AG: 17 Million yr</p><p>Rozerem: $52 Million yr</p><p>Generics: $170 Million yr</p><p>Nesina & Oseni- ?</p><p>Omontys?</p><p>Actos 6months 1.6Billion</p><p><br /></p><p>Total without Actos or Nesina products</p><p> $1,593,000,000</p><p><br /></p><p>With Actos 6 months</p><p><br /></p><p>$3,195,000,000</p><p><br /></p><p>With Actos 6 months Branded, Nesina & Oseni, Omontys, and some growth of exisiting products?</p><p><br /></p><p>$3.3-3.5 Billion in 2012.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 4332720"]Well first off your rules are wrong. Last I checked revenue is all money coming in not just a certain selected group of income earners. Obviously the field sales products will not be generating the huge sales revenue like the past. Leadership has acknowledge this and stated the plan is to bottom the next several years and regain growth as new products enter the market and others grow...something like 2017ish return to past revenue. So with that as the plan you DO INCLUDE all products knowing that they are bridging us to the future. These are from 3rd qtr and do not include any grow factor. Dexilant: $296 Million yr Uloric: $160 Million yr Edarbi/Family $4 Million yr (much higher then these #'s) Amitiza: $232 Million yr Colcyrs: $430 Million yr Prevacid: $232 Million yr Prevacid AG: 17 Million yr Rozerem: $52 Million yr Generics: $170 Million yr Nesina & Oseni- ? Omontys? Actos 6months 1.6Billion Total without Actos or Nesina products $1,593,000,000 With Actos 6 months $3,195,000,000 With Actos 6 months Branded, Nesina & Oseni, Omontys, and some growth of exisiting products? $3.3-3.5 Billion in 2012.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Takeda
>
Did Yasu say...No more layoffs?
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Takeda
>
Did Yasu say...No more layoffs?
>